Form 4: Director Thomas Kirk Increases Stake in Myomo, Inc.

Director Thomas F. Kirk acquired 75,006 shares of Myomo, Inc. common stock through open market purchases.

Summary

• Director Thomas F. Kirk purchased a total of 75,006 shares of Myomo, Inc. (MYO) common stock.
• The purchases occurred in two separate transactions on May 15, 2026, and May 18, 2026.
• The first transaction involved 31,605 shares at a weighted average price of $0.9096 per share.
• The second transaction involved 43,401 shares at a weighted average price of $0.91 per share.
• Following these transactions, the director's total beneficial ownership increased to 628,863 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as director-level open market buying typically indicates confidence in the company's future performance.

Positives

• Insider confidence is demonstrated by the director's decision to increase his equity stake in the company through open market purchases.
• The purchases were made at prices near $0.91, suggesting the director views the current valuation as attractive.

Negatives

• None identified in this filing.

Risks

• The company's stock price remains sensitive to market volatility and the execution of its business strategy.

Future Outlook

No specific forward-looking guidance was provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal of management's belief in the long-term prospects of the company, particularly in the medical device sector where capital allocation and growth milestones are critical.

Comparison to Industry Standards

• Insider purchases by board members are standard practice and often serve as a signal of alignment with shareholder interests.
• The purchase volume is consistent with typical director-level equity accumulation in small-cap medical technology firms.

Stakeholder Impact

• Shareholders may interpret this as a sign of stability and confidence from the board of directors.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Myomo, MYO, Insider Trading, Director Purchase, Equity Ownership, Medical Technology